מקורות רשמיים ומחקרים

Wegovy US Prescribing Information

Ozempic US Prescribing Information

Mounjaro US Prescribing Information

Zepbound US Prescribing Information

STEP-1 Trial

SURMOUNT-1 Trial and Follow-up

SELECT Trial

SURMOUNT-OSA Trial

SURMOUNT-5 Head-to-Head Trial

2023 International PCOS Guideline

ADA 2026 Pharmacologic Treatment of Obesity in Adults

ATS Guideline on Weight Management in Adult OSA

Semaglutide in MASH, NEJM 2025

Israel Ministry of Health Drug Prices

Israeli Drug Index

Kol Habriut Wegovy Product Page

Kol Habriut Ozempic Product Page

Maccabi obesity and diabetes injections page

Maccabi Mounjaro medicine page

Maccabi Ozempic medicine page

Clalit Wegovy rights page

Clalit Ozempic Rybelsus rights page

Leumit weight-loss drug page

Leumit guide to weight-loss injections

Leumit medicine search

Meuhedet Mounjaro subsidy page

EMA Wegovy update

FDA approval of Zepbound for OSA

FDA Drug Trials Snapshot: Mounjaro

FDA Wegovy cardiovascular risk indication approval

FDA Wegovy HD approval

SUSTAIN-6 Trial

FLOW Trial

SOUL Trial

Saxenda US Prescribing Information

SCALE Obesity and Prediabetes Trial

FDA adolescent Saxenda approval update

Liraglutide in Adolescents with Obesity Trial

Mayo Clinic Diet: Managing common side effects from weight-loss drugs

NIDDK: Prescription Medications to Treat Overweight and Obesity

WHO: Obesity GLP-1 therapies Q&A

Mayo Clinic: Semaglutide oral route

Mayo Clinic News Network: Supporting weight-loss medications with adequate nutrition

The Obesity Society: Nutritional Priorities to Support GLP-1 Therapy for Obesity

Obesity Medicine Association: Strategies to Minimize Muscle Loss

SURMOUNT-4 Tirzepatide Maintenance Randomized Trial

STEP 1 Trial Extension After Semaglutide Withdrawal

Mayo Clinic: Prescription weight-loss drugs

NIDDK: Treatment for Overweight and Obesity